Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma

Oncology Letters

Volumn 8, Issue 3, 2014, Pages 1249-1254

  Hou, Wenmin ^a,b   Liu, Jibin ^b,c   Chen, Peizhan ^b   Wang, Hui ^b   Ye, Bang Ce ^a   Qiang, Fulin ^c  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c Tumor Hospital of Nantong City   (China)

Author keywords

Cancer related genes; Hepatocellular carcinoma; KRAS; Mutation analysis

Indexed keywords

EID: 84904258206     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2253     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. McGlynn KA and London WT: The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 15: 223-243, vii-x, 2011.
3. Owonikoko TK and Khuri FR: Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book: 2013. doi: 10.1200/EdBook_AM.2013.33.e395.
4. McCubrey JA, Steelman LS, Abrams SL, et al: Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22: 708-722, 2008.
5. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22, 2003.
6. Zheng Y, Li J, Johnson DL and Ou JH: Regulation of hepatitis B virus replication by the ras-mitogen-activated protein kinase signaling pathway. J Virol 77: 7707-7712, 2003.
7. Liu H, Xu J, Zhou L, et al: Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res 71: 7547-7557, 2011.
8. Steelman LS, Chappell WH, Abrams SL, et al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 3: 192-222, 2011.
9. Fernández-Medarde A and Santos E: Ras in cancer and developmental diseases. Genes Cancer 2: 344-358, 2011.
10. Fransén K, Klintenäs M, Osterström A, Dimberg J, Monstein HJ and Söderkvist P: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25: 527-533, 2004.
11. Libra M, Malaponte G, Navolanic PM, et al: Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 4: 1382-1384, 2005.
12. Fukushima T, Suzuki S, Mashiko M, et al: BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22: 6455-6457, 2003.
13. Roymans D and Slegers H: Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem 268: 487-498, 2001.
14. Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554, 2004.
15. Lee JW, Soung YH, Kim SY, et al: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24: 1477-1480, 2005.
16. Shayesteh L, Lu Y, Kuo WL, et al: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21: 99-102, 1999.
17. Ligresti G, Militello L, Steelman LS, et al: PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 8: 1352-1358, 2009.
18. Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M and Bell DW: PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res 71: 4061-4067, 2011.
19. Philp AJ, Campbell IG, Leet C, et al: The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61: 7426-7429, 2001.
20. Stambolic V, Suzuki A, de la Pompa JL, et al: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39, 1998.
21. Tamguney T and Stokoe D: New insights into PTEN. J Cell Sci 120: 4071-4079, 2007.
22. Chappell WH, Steelman LS, Long JM, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2: 135-164, 2011.
23. Llovet JM, Bru C and Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338, 1999.
24. Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: D945-D950, 2011.
25. Zhu AX: Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112: 250-259, 2008.
26. De La O JP and Murtaugh LC: Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling. Cell Cycle 8: 1860-1864, 2009.
27. Tannapfel A, Sommerer F, Benicke M, et al: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52: 706-712, 2003.
28. Balschun K, Haag J, Wenke AK, von Schonfels W, Schwarz NT and Rocken C: KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. J Mol Diagn 13: 436-445, 2011.
29. Fujimoto A, Totoki Y, Abe T, et al: Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44: 760-764, 2012.
30. Guichard C, Amaddeo G, Imbeaud S, et al: Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44: 694-698, 2012.
31. Huang J, Deng Q, Wang Q, et al: Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 44: 1117-1121, 2012.
32. Challen C, Guo K, Collier JD, Cavanagh D and Bassendine MF: Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol 14: 342-346, 1992.
33. Taketomi A, Shirabe K, Muto J, et al: A rare point mutation in the Ras oncogene in hepatocellular carcinoma. Surg Today 43: 289-292, 2013.
34. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC and Tran E: Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3: 19, 2003.
35. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712, 2008.
36. Zuo Q, Huang H, Shi M, et al: Multivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinoma. Anat Rec (Hoboken) 295: 423-431, 2012.
37. Colombino M, Sperlongano P, Izzo F, et al: BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis 3: e259, 2012.
38. Tanaka Y, Kanai F, Tada M, et al: Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 25: 2950-2952, 2006.
39. Riener MO, Bawohl M, Clavien PA and Jochum W: Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer 47: 363-367, 2008.
40. Li X, Zhang Q, He W, et al: Low frequency of PIK3CA gene mutations in hepatocellular carcinoma in Chinese population. Pathol Oncol Res 18: 57-60, 2012.
41. Bae JJ, Rho JW, Lee TJ, et al: Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients. Oncol Rep 18: 1007-1013, 2007.
42. Wang L, Wang WL, Zhang Y, Guo SP, Zhang J and Li QL: Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 37: 389-396, 2007.
43. Tsuda H, Hirohashi S, Shimosato Y, Ino Y, Yoshida T and Terada M: Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res 80: 196-199, 1989.
44. Taniguchi K, Yamada T, Sasaki Y and Kato K: Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma. BMC Cancer 10: 530, 2010.
45. Tada M, Omata M and Ohto M: Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res 50: 1121-1124, 1990.
46. Bose S, Sakhuja P, Bezawada L, et al: Hepatocellular carcinoma with persistent hepatitis B virus infection shows unusual downregulation of Ras expression and differential response to Ras mediated signaling. J Gastroenterol Hepatol 26: 135-144, 2011.
47. Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R and Tannapfel A: Frequent k-ras-2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer 84: 982-989, 2001.